Earth Science Tech, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ETST research report →
Price Chart
About the company
Earth Science Tech, Inc. (EST) is a biotechnology firm dedicated to the worldwide development and distribution of nutraceuticals, bioceuticals, and dietary supplements. These offerings aim to support general health, overall well-being, nutrition, and address specific needs within the cosmetic and alternative medicine sectors.
- CEO
- Giorgio R. Saumat
- IPO
- 2014
- Employees
- 77
- HQ
- Miami, FL, US
Get TickerSpark's AI analysis on ETST
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $27.20M
- P/E
- 7.10
- Fwd P/E
- 9.44
- PEG
- 0.14
- P/S
- 0.76
- P/B
- 3.73
- EV/EBITDA
- 5.45
- Div Yield
- 0.00%
- Gross Margin
- 53.77%
- Op Margin
- 12.95%
- Net Margin
- 10.82%
- ROE
- 62.03%
- ROIC
- 60.36%
Latest fiscal year · YoY change
- Revenue
- $35.70M+7.8%
- Gross Profit
- $25.49M+4.9%
- Op Income
- $4.31M
- Net Income
- $3.63M+11.6%
- EPS
- $0.01+15.9%
- OCF Growth
- -55.6%
- FCF Growth
- -67.3%
- 52W High
- $0.24
- 52W Low
- $0.00
- 50D MA
- $0.09
- 200D MA
- $0.13
- Beta
- 2.47
- RSI (14)
- 47
- Avg Volume
- 121.94K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Earth Science Tech said the quarter was still shell-like, but management focused on its newly merged pharmacy businesses and a path toward cash flow positive, OTCQB uplisting, and more acquisitions.· November 14, 2022
- Reported Q2 fiscal 2023 loss was $228,000, with only $1,205 of cash at September 30.
- Management said the company has now merged with RxCompound Store and Peaks and is operating as a holding company.
- The team is targeting cash flow positive as soon as possible, potentially early to mid-next year, but gave no firm timeline.
- Board expansion is planned, including at least one independent legal professional and one medical professional, with those seats expected to be announced by end of December.
- OTCQB uplisting work is underway, tied to audits for RxCompound Store and Peaks and a super 8-K filing.
For the quarter ended September 30, management said Earth Science Tech lost $228,000 and ended with $1,205 in cash. No revenue, EPS, or gross margin figures were stated on the call. Looking ahead, management said it is working toward cash flow positive, but would not commit to a firm date; one answer suggested it could be “early to mid-next year” if progress continues. They also said they are aiming to complete audits, file a super 8-K, remedy the 211 portal issue, and apply for OTCQB, potentially by the end of the year or early next year.
Giorgio Saumat framed the quarter as largely a transition period because the company had been “basically a shell” and emphasized that the real story is the post-quarter transformation. He said the merger with RxCompound Store and Peaks converts ETST into a holding entity and that the company is actively pursuing additional acquisitions. His tone was upbeat and forward-looking, but he was careful not to provide hard dates on the board, cash flow, or other milestones.
Nickolas Tabraue focused on liquidity, balance sheet cleanup, and the operational bridge to cash flow positive. He said the company had only $1,205 in cash at quarter-end, but management believes it currently has enough cash on hand to fund operations while it continues reducing liabilities with creditors. He also said he and Mario agreed to no executive compensation until the company becomes cash flow positive, and that the board should help decide future compensation and cash use once the company reaches that milestone.
Analyst questions centered on the timing of cash flow positivity, independent directors, cash sufficiency, the sterile room, OTCQB timing, state licensing, and what would happen with excess cash. Management said the sterile room and hazardous room are important because they expand compounding capacity, especially injectables, and could become a major revenue driver; they also said Florida and New York are currently licensed while other states are coming later. On OTCQB, they said the path depends on completing audits and filings, with a target of later this year or early next year, but acknowledged some factors are outside their control.
The bullish case is that management believes the operational turnaround has accelerated, with a merger into RxCompound Store and Peaks already completed and more acquisitions possible. They highlighted new compounding capabilities, growing state licensing, and a plan to avoid executive compensation until the business is cash flow positive, which they presented as shareholder-aligned.
The main risks are that the company just reported a $228,000 loss and ended the quarter with only $1,205 in cash, which underscores how early the turnaround still is. Management repeatedly avoided firm timelines for cash flow positive, OTCQB, and board additions, and they acknowledged reliance on audits, other people, and creditor negotiations that could slow execution.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 31.0%
- Shares Outstanding
- 288.17M
- Float Shares
- 89.26M
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 22, 25 | Saumat Giorgio R. | buy | 50,000 |
| Jul 21, 25 | Saumat Giorgio R. | buy | 100,000 |
| Jul 9, 25 | Sanchez Yovan Arturo | buy | 1,349 |
| Jul 9, 25 | Sanchez Yovan Arturo | buy | 20,459 |
| Jul 9, 25 | Sanchez Yovan Arturo | buy | 131 |
| Jul 8, 25 | Sanchez Yovan Arturo | buy | 11,105 |
| Jul 2, 25 | Sanchez Yovan Arturo | buy | 60,805 |
| Mar 14, 25 | Sanchez Yovan Arturo | buy | 100,000 |
| Mar 10, 25 | Tabraue Mario Guillermo | buy | 40,000 |
| Mar 4, 25 | Rose Christopher Alan | buy | 21,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ETST coverage
Recent articles, reports, and earnings notes.
No research on ETST yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ETST report →Earth Science Tech, Inc. Uplists to OTCQB Venture Market
globenewswire.com · Sep 16
Earth Science Tech, Inc. (OTCMKTS:ETST) Sees Significant Decrease in Short Interest
defenseworld.net · Sep 3
Earth Science Tech, Inc. Announces 2026 Annual Shareholder Meeting Results
globenewswire.com · Sep 1
Earth Science Tech, Inc. (ETST) Shareholder/Analyst Call Transcript
seekingalpha.com · Aug 31
Earth Science Tech, Inc. (ETST) Acquires Zoolzy LLC to Drive Margin Expansion and Strategic Entry into the Veterinary Market
globenewswire.com · Aug 19
Earth Science Tech, Inc. (ETST) Expands National Footprint with Strategic Acquisition of California Compounding Pharmacy, Meduvo LLC
globenewswire.com · Aug 12
Earth Science Tech, Inc. (ETST) Reports Fiscal First Quarter 2027 Financial Results for the Period Ended June 30, 2026
globenewswire.com · Aug 7
Earth Science Tech, Inc. Reports Fiscal Year-End Financial Results for March 31, 2026
globenewswire.com · Jun 18
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.